Payment overview · 2025
General Payments
$671.04
32 reported records · 17 companies
Healthcare provider profile · identity verified
Traci Lynn Boyd, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · GRAYSON, KY · NPI 1245594811
Verified facts
What the public records show
CMS Open Payments records show Traci Lynn Boyd, APRN received $671.04 in general payments during 2025 across 32 reported records.
Grifols USA, LLC accounted for 13.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $88.51 | 13.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $80.09 | 11.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $62.73 | 9.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $60.28 | 9.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.90 | 8.8% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $36.78 | 5.5% | 2 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $35.60 | 5.3% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $34.24 | 5.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.07 | 4.9% | 2 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $29.26 | 4.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.16 | 4.3% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $24.67 | 3.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $24.07 | 3.6% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $20.98 | 3.1% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $20.05 | 3.0% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $17.40 | 2.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.25 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $671.04 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $88.51 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $80.09 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $62.73 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $60.28 | 3 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $45.65 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $44.18 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $36.78 | 2 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $35.60 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $34.24 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.07 | 2 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $29.26 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.16 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $24.07 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
59 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
64 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 320 | 88 |
| Omeprazole | Omeprazole | 204 | 47 |
| Lisinopril | Lisinopril | 185 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 181 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 180 | 46 |
| Tizanidine Hcl | Tizanidine Hcl | 153 | 41 |
| Levothyroxine Sodium | Levothyroxine Sodium | 143 | 44 |
| Losartan Potassium | Losartan Potassium | 140 | 35 |
| Potassium Chloride | Potassium Chloride | 137 | 36 |
| Furosemide | Furosemide | 131 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 35 |
| Trazodone Hcl | Trazodone Hcl | 113 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 30 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 99 | 26 |
| Carvedilol | Carvedilol | 98 | 26 |
| Prednisone | Prednisone | 87 | 54 |
| Metformin Hcl | Metformin Hcl | 84 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 83 | 18 |
| Gabapentin | Gabapentin | 82 | 16 |
| Simvastatin | Simvastatin | 82 | 16 |
| Ozempic | Semaglutide | 80 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 19 |
| Montelukast Sodium | Montelukast Sodium | 78 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 19 |
| Buspirone Hcl | Buspirone Hcl | 76 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 69 | 17 |
| Ibuprofen | Ibuprofen | 67 | 20 |
| Eliquis | Apixaban | 64 | 17 |
| Trulicity | Dulaglutide | 59 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 58 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 15 |
| Tramadol Hcl | Tramadol Hcl | 55 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 54 | 15 |
| Bupropion Xl | Bupropion Hcl | 52 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 11 |
| Ezetimibe | Ezetimibe | 50 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 15 |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 46 | 14 |
| Ondansetron Odt | Ondansetron | 44 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 43 | 17 |
| Alprazolam | Alprazolam | 41 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 13 |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Meloxicam | Meloxicam | 38 | 13 |
| Sucralfate | Sucralfate | 38 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 36 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Linzess | Linaclotide | 35 | suppressed |
| Glimepiride | Glimepiride | 34 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Famotidine | Famotidine | 32 | 14 |
| Topiramate | Topiramate | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Ibu | Ibuprofen | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 12 |
| Glipizide | Glipizide | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Allopurinol | Allopurinol | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 16 |
| Meclizine Hcl | Meclizine Hcl | 19 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $671.04 · 32 records | Grifols USA, LLC | AUSTEDO XR, CAPLYTA, COLLAGENASE SANTYL, Cologuard Collection Kit, DUPIXENT, Dexcom G6 Transmitter, INSPIRE, Jornay PM, Korlym, MOUNJARO, NURTEC ODT, Ohtuvayre, Prolastin-C Liquid, QULIPTA, TRELEGY ELLIPTA, VRAYLAR, WAKIX | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error